All News
What would it take for JAKs to ROCK the boat?
JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we have seen phase 2 results for CPL’116, and a simultaneous publication in The Lancet Rheumatology.
Read Article
Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases
During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR 2025, data from Phase 2 RCT of efgartigimod, an FcRn-inhibitor were presented in autoantibodies positive, moderate to severe active SjD. In addition to SjD, data from Phase 2 RCT of efgartigimod in inflammatory myopathies was presented.
Read Article
Lessons on Uveitis and AxSpA
Dr. Adela Castro reporting from the 2025 EULAR meeting in Barcelona
https://t.co/G0lDGDhpTh https://t.co/UWBSgTLyQm
Dr. John Cush RheumNow ( View Tweet)
DMARD Combinations in RA Treatment
Dr. Jiha Lee discusses abstract OP0195 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/lrZRDvWD0z https://t.co/PS4k2bCqet
Dr. John Cush RheumNow ( View Tweet)
Deucravacitinib's Place in the PsA Treatment Algorithm?
Dr. Eric Ruderman offers his perspective on where deucravacitinib will fit in the treatment algorithm and trials presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/6Ozrvr5IMt https://t.co/w7FJs4wir9
Dr. John Cush RheumNow ( View Tweet)
JAK Safety Update
Dr. Jonathan Kay offers his perspectives on abstracts POS0150, POS0151, and POS0157 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/F8WzGohCj8 https://t.co/FguBLrmPzZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Harnessing AI in axSpA: The Promise of Digital Therapeutics with Axia
The management of axial spondyloarthritis (axSpA) continues to evolve with the integration of artificial intelligence (AI) and digital health technologies. Traditionally, treatment has centered around https://t.co/5CCpZqkm7K
Dr. John Cush RheumNow ( View Tweet)
2025 update of EULAR recommendations on lupus nephritis
At the 2025 EULAR congress in Barcelona, Prof Dimitrios Boumpas presented updated EULAR recommendations on managing lupus nephritis (LN). The key change is that the historic standard of care (mycophenolate with https://t.co/hMOoTxffwH
Dr. John Cush RheumNow ( View Tweet)
Pregnancy outcomes in autoinflammatory disease
To address this, a French multi-centre prospective pregnancy observational cohort was set up, to analyse disease activity, treatment, pregnancy outcomes, delivery, and neonatal health. The work – presented at the 2025 annual https://t.co/oQ7A2bnDmO
Dr. John Cush RheumNow ( View Tweet)
Vector borne diseases that result in arthritis will rise with climate change/ flooding risk
- Chikungunya
- Dengue
- Zika
- West-Nile Virus
@RheumNow #EULAR2025 @bella_mehta https://t.co/CCOYqTjaXE
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid arthritis incidence has risen to 17.9 million people globally -13.2% increase from 1990-2021. Fewer people are dying from RA, but disability-adjusted life Yrs have doubled. high sociodemographic index bore the heaviest burden. Smoking control policies is forecasted to https://t.co/YOMSIXys0j
Dr. John Cush RheumNow ( View Tweet)
From Domains to Decisions: Personalizing PsA Care with Data
At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; https://t.co/tzgE7U4eSj
Dr. John Cush RheumNow ( View Tweet)
#EULAR2025 TriNetX database study indicated that fibromyalgia patients who used glucagon-like peptide-1 (GLP-1) receptor agonist drugs were less likely to use opioids and to report pain, fatigue, and malaise compared with propensity-matched non-users https://t.co/ftm93VwW65 https://t.co/GpC7QliKXH
Dr. John Cush RheumNow ( View Tweet)
New ideas in gout management
Gout flares are associated with cardiovascular events. Treating gout to target serum urate level prevents flares, but whether such treatment can also prevent cardiovascular events is unknown.
https://t.co/C8G39JzP9Y https://t.co/NAClL0JLGX
Dr. John Cush RheumNow ( View Tweet)
Reviewing Three Osteoarthritis Studies
Dr. Janet Pope discusses abstracts POS0492, abstract POS0565, and abstract POS0612 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/0qub4ITnxa https://t.co/uguzPSnvCR
Dr. John Cush RheumNow ( View Tweet)
Which CAR T Cell is Mighty?
Dr. Yuz Yusof talks with Dr. Chris Wincup about CAR T data being presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/MkRoqlvdub https://t.co/R0dtllmo7Q
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – Day 3 Report
Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treating high-risk pre-clinical RA, and EULAR Recommendations on ILD treatment, physical activity for arthritis, the EULAR disease activity score for antiphospholipid https://t.co/FAaj443wPX
Dr. John Cush RheumNow ( View Tweet)
Imaging and Early Detection in Psoriatic Arthritis
At EULAR 2025, there have been new developments in imaging in PsA. Two key poster presentations (POS0104 and OP0179) provide important insights into the role of imaging in the management and early detection of psoriatic https://t.co/41fgXj5WnN
Dr. John Cush RheumNow ( View Tweet)
Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/35cWYRehdd
Dr. John Cush RheumNow ( View Tweet)
Predictors and Outcomes in Systemic Sclerosis
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/9dJn1qMQfy
Dr. John Cush RheumNow ( View Tweet)